ArticleHealth science reports2025
Seroepidemiological Study of Parvovirus B19 Infection Among Pregnant Women Attending Ayatollah Rohani Hospital in Babol, Iran: A Cross-Sectional Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Parvovirus B19 is a common viral pathogen associated with a variety of clinical manifestations, including significant complications during pregnancy such as fetal anemia, miscarriage, and hydrops fetalis. Determining the seroprevalence of B19-specific antibodies in pregnant women is essential for assessing population immunity and potential risk to the fetus. This study aimed to evaluate the seroprevalence of IgG and IgM antibodies against parvovirus B19 among pregnant women attending Ayatollah Rouhani Hospital in Babol, Iran. Methods: A cross-sectional study was conducted on 247 pregnant women in 2018. Serum samples were analyzed for parvovirus B19-specific IgG and IgM antibodies using enzyme-linked immunosorbent assay (ELISA). Associations between seropositivity and demographic/clinical variables were statistically analyzed. Results: Out of the 247 participants, 124 (50%) were seropositive for B19-specific IgG, indicating previous exposure. Additionally, 10 of 90 women (11.1%) tested positive for IgM antibodies, suggesting recent infection. No statistically significant associations were found between seropositivity and variables such as age, gestational age, or history of miscarriage in the multivariate analysis, although parity showed significance in the univariate analysis. Conclusion: Approximately half of the studied pregnant women had no detectable immunity to parvovirus B19 and were at risk of primary infection during pregnancy. The presence of IgM antibodies in a subset of women highlights the need for increased awareness, routine screening, and preventive strategies to mitigate the risk of vertical transmission and adverse fetal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.